Baxalta Bails On Onconova After Phase III Study Launch
This article was originally published in Scrip
Executive Summary
Onconova Therapeutics Inc. said on March 3 that Baxalta US Inc. backed out of a deal to co-develop intravenous rigosertib three months after the companies began the Phase III INSPIRE clinical trial that will enroll 225 patients with high-risk myelodysplastic syndromes (HR-MDS).